SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-052907
Filing Date
2023-04-28
Accepted
2023-04-28 16:05:11
Documents
6
Period of Report
2023-06-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2313950d1_def14a.htm DEF 14A 482441
2 GRAPHIC tm2313950d1_def14aimg001.jpg GRAPHIC 3540
3 GRAPHIC tm2313950d1_def14aimg002.jpg GRAPHIC 237674
4 GRAPHIC tm2313950d1_def14aimg003.jpg GRAPHIC 226529
5 GRAPHIC tm2313950d1_def14aimg004.jpg GRAPHIC 4385
6 GRAPHIC tm2313950d1_def14aimg005.jpg GRAPHIC 4643
  Complete submission text file 0001104659-23-052907.txt   1140840
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

IRS No.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41264 | Film No.: 23865856
SIC: 2834 Pharmaceutical Preparations